Opmerkingen bij de notitie Dwanglicenties van B.J. Bruins, Minister voor Medische Zorg.

By Ellen ‘t Hoen, Global Health Unit Department of Health Sciences, UMCG Groningen, e.f.m.t.hoen@umcg.nl.

Op 15 juni 2018 stuurde Minister Bruins een notitie over dwanglicenties aan de Tweede Kamer. In deze briefing maken wij een aantal voorlopige opmerkingen op de notitie van de Minister. Vragen en opmerkingen zijn welkom: info@medicineslawandpolicy.net

Continue reading


Voices in the Field: Eva Zhang

In celebration of her upcoming PhD defence on 28 May, Voices in the Field interviewed Eva Zhang about her experience as a researcher specialising in the right to health in China. Zhang’s thesis, entitled ‘Advancing the Right to Health Care in China – Towards Accountability’ looked into accountability for the implementation of the right to health in China, and the various mechanisms such accountability might take. Zhang is also the Chinese liaison of the GHLG Research Centre, in which she establishes relationships between universities and research institutions in the Netherlands and China.

Continue reading

Let’s talk about the sugartax – Laten we praten over de suikertaks

By Professor Brigit Toebes, Academic Director, Global Health Law Groningen Research Centre

English: The sugar tax does not receive the attention it deserves in the Netherlands. Research indicates that a price increase of fizzy drinks in particular can reduce its consumption. It is time for a more concerted governmental, societal, and scientific debate in the Netherlands about the pros and cons of this measure.

Nederlands: de suikertaks krijgt niet de aandacht die hij verdient in Nederland. Onderzoek toont aan dat een prijsverhoging van met name frisdrank de consumptie ervan kan verlagen, hetgeen kan bijdragen aan het terugdringen van overgewicht.

Continue reading

The Effect of Laws and Policies About Foreign Aid on Access to Reproductive Health Services

By Dean M. Harris, J.D., Associate Professor, Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA, Dean_Harris@unc.edu

In January of 2017, I wrote a blog post for Global Health Law Groningen about the global health effects of the 2016 U.S. election. I wrote it a few days before the inauguration of a new president. At that time, I made some predictions about the likely effects of the election on the U.S. role in global health.

I wish that my predictions had been wrong. In fact, the actual results have been worse than anticipated. My predictions in January of 2017 were that “It is very likely that the change of government in the U.S. will: (1) reduce access to reproductive health services; (2) change the amounts and priorities of development aid from the U.S. government; (3) reduce progress in responding to global environmental problems; and (4) change U.S. immigration policies in ways that adversely affect other countries.”[1] Specifically, I noted that the new president might reinstate the U.S. government’s Mexico City Policy, which critics call the “global gag rule.”[2]

Continue reading

European Commission Publishes Expert Panel’s Recommendations on High Drug Prices

By Ellen ‘t Hoen, Global Health Unit Department of Health Sciences, UMCG Groningen, e.f.m.t.hoen@umcg.nl. 

This month the European Commission published Innovative Payment Models for High-Cost Innovative Medicines, a report of the Expert Panel on effective ways of investing in Health (EXPH).

The report examines new ways of paying for new and costly medicines as a means to finding solutions for the ever-increasing prices of new pharmaceutical treatments. The panel does not shy away from exploring hot-button topics such as the need for greater transparency in medicines pricing, R&D and marketing cost, enlisting competition authorities to investigate drug pricing, ‘orphanisation’ of new medicines, revisiting the patent and market exclusivity as a cornerstone of innovation, developing alternative paths for innovation financing based on delinkage principles such as prize awards and the question how to ensure a ‘public return on public investment’. It further explores ways to bolster negotiating power of governments in price negotiations, including through the use of compulsory licensing of medicines patents.

Continue reading

Invitation and Call for Abstracts: ‘Law and Noncommunicable Diseases’ 31 May – 1 June 2018

The European Scientific Network on Law and Tobacco (ESNLT) as led by the Global Health Law Groningen Research Centre of the University of Groningen, and the Leuven Institute for Healthcare Policy and the Leuven Centre for Public Law of the KU Leuven with support of the European Association of Health Law, cordially invite you to the conference:

Law and Noncommunicable Diseases:
The cross-cutting role of law in NCD control and regulating risk factors
31 May – 1 June 2018 in Groningen, The Netherlands

Continue reading